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Aim. Intravenous leiomyomatosis (IVL) with cardiac extension (CE) is a rare variant of benign uterine leiomyoma. Incomplete
resection has a recurrence rate of over 30%. Different hormonal treatments have been described following incomplete resection;
however no standard therapy currently exists. We review the literature for medical treatments options following incomplete
resection of IVL with CE. Methods. Electronic databases were searched for all studies reporting IVL with CE. These studies were
then searched for reports of patients with inoperable or incomplete resection and any furthermedical treatments. Our database was
searched for patients with medical therapy following incomplete resection of IVL with CE and their results were included. Results.
All studies were either case reports or case series. Five literature reviews confirm that surgery is the only treatment to achieve
cure.The uses of progesterone, estrogen modulation, gonadotropin-releasing hormone antagonism, and aromatase inhibition have
been described following incomplete resection. Currently no studies have reviewed the outcomes of these treatments. Conclusions.
Complete surgical resection is the only means of cure for IVL with CE, while multiple hormonal therapies have been used with
varying results following incomplete resection. Aromatase inhibitors are the only reported treatment to prevent tumor progression
or recurrence in patients with incompletely resected IVL with CE.
1. Introduction
Intravenous leiomyomatosis (IVL) with cardiac extension
(CE) is a rare variant of otherwise usually benign uterine
leiomyoma. Complete surgical excision is the only means of
curative treatment. However this may not be technically fea-
sible or individually desirable from the patient’s perspective
with combined thoracoabdominal operation usually required
to achieve complete resection. Given the high recurrence rate
following incomplete surgical resection, the use of adjuvant
hormonal therapy has been investigated in an attempt to
control or eradicate remnant disease. These agents have been
used with varying success in patients with incompletely
resected disease. This review discusses the use of hormonal
treatment of IVL with CE, with two cases demonstrating
the effective use of aromatase inhibitor therapy in both the
short and long term when complete surgical resection is not
achieved.
2. Methods
Electronic databases were searched for the terms “intra-
venous leiomyoma” OR “intravenous leiomyomatosis” OR
“intravascular leiomyoma” OR “intravascular leiomyomato-
sis” AND “cardiac extension” OR “extension to the heart”
OR “intracardiac” OR “intracardiac extension”. These results
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Figure 1: (a) Hypodense filling defect in the IVC on CT and (b) free-floating echodensity at the level of the hepatic veins, both consistent
with intracaval thrombus.
were then individually searched for cases of hormonal or
medical treatment following incomplete resection. The term
“benign metastasizing leiomyoma” (BML) was also included
in our literature search as this pathology is similar to IVL
and some authors describe treatments for both BML and IVL
in their series. Each article was then individually reviewed
to confirm cases or reports of cardiac extension of IVL.
The references of the articles retrieved were also reviewed
in order to identify any further relevant studies. All studies
including case reports, case series, and original articles were
included. Studies were limited to those published in the
English language.
The cardiothoracic database at our institution was
searched for any patients who had undergone sternotomy for
resection of intravenous tumors with cardiac extension, from
the inception of our unit database to the present. The cases
identified had their pathology reports checked to identify
the presence of IVL with CE. The medical records of these
patients were accessed to identify the degree of surgical
resection and any treatments given following incomplete
resection. Outcomes were determined from specialist follow-
up reports.
3. Results
All articles identified were case reports or case series. All
available reports of hormonal therapy for IVL with CE
are included in this review. Two articles reported on both
BML and included cases of IVL in their reports. Five
articles included literature reviews of IVL with CE. These
studies discuss diagnosis, treatment, in particular surgical
strategies, and outcomes. Hormonal therapies have included
progesterone, estrogen modulators, hypothalamic-pituitary
axis suppression of gonadotropin-releasing hormone, and
estrogen antagonism. While the use of these hormonal
agents as therapy following incomplete surgical resection is
discussed in individual studies, there is currently no study
investigating the outcomes for each individual hormonal
agent.
Two cases were identified from our records of incomplete
resection of IVL with CE. Both patients received hormonal
therapy following surgical treatment. They are included in
this review as their results contribute significantly to the
available literature.
3.1. Case 1. A 53-year-old female was reported to have a free-
floating thrombus in her inferior vena cava (IVC) identified
on computed tomography (CT) of the abdomen, eight weeks
following a right oophorectomy for an ovarian mass. The
thrombus extended from the right external iliac vein to the
level of the hepatic veins (Figure 1). She had undergone a
hysterectomy and left oophorectomy eight years earlier for
a uterine fibroid and left ovarian cyst. A diagnosis of IVL
was established on her pathology specimen at that time;
however the patient was lost to follow-up and no further
action was taken. Following this new finding on CT, she
underwent a combined sternolaparotomy with cardiopul-
monary bypass (CPB) and ten-minute deep hypothermic
circulatory arrest (DHCA). The IVC was opened and a
smooth, firm white-colored tumor was resected with no
need for further cardiotomy. She recovered uneventfully
and was seen in outpatient follow-up 10 days later with no
postoperative problems. Histopathology identified a 130mm
long rubbery cream tumor, with smoothmuscle proliferation,
variable cellularity, and organized thrombus, consistent with
IVL. Specifically there were no features to warrant desig-
nation as borderline or malignant smooth muscle tumor
and all features were typical of leiomyoma. During follow-
up she developed bilateral pulmonary lesions that were not
amenable to biopsy. She was treated with Tamoxifen 20mg
daily based on the strong estrogen and progesterone receptor
positivity of her initial tumor. The lung lesions were stable
following three months of therapy; however at 12 months
her therapy was changed to Anastrozole as the nodules had
progressed in size. 11 years following the commencement of
Anastrozole the lung nodules remained stable and the patient
remains asymptomatic.
3.2. Case 2. A 62-year-old female was found to have bilateral
pulmonary emboli on computed tomography pulmonary
angiography (CTPA) following two episodes of syncope
(Figure 2(a)). She underwent transthoracic echocardiogra-
phy (TTE) and a large, mobile thrombus was reported in
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Figure 2: (a) Right and left pulmonary artery filling defects on CTPA and (b) TOE demonstrating the head of the mass protruding from the
IVC into the RA. The TV was not damaged although the mass protruded through the TV into the RV during diastole. IVC: inferior vena
cava; RA: right atrium; TV: tricuspid valve; RV: right ventricle.
(a) (b) (c)
Figure 3: (a) A thin, white mass in the RA with its attachment extending down the IVC and (b) the gross specimen of the intracardiac tumor.
(c) Smooth muscle actin antibody stain positive in the tumor specimen.
her right atrium (RA) and IVC (Figure 2(b)). She under-
went emergency removal of the intracardiac mass and a
large, white tumor mass protruded through the atriotomy
when the right atrium was opened for venous cannulation
for cardiopulmonary bypass (Figure 3(a)). The right atri-
otomy was extended and the mass was well visualized and
divided at its apparent attachment to the IVC (Figure 3(b)).
Histopathology identified a low-cellularity fibrous tumor
with smooth muscle cells, with no areas of necrosis or atypia.
Immunostaining was positive for smooth muscle actin and
desmin, confirming the diagnosis of IVL (Figure 3(c)). Fur-
ther abdominal imaging with CT identified a distended IVC,
right common iliac vein, and right internal iliac vein, filled
with low-density intraluminal material and a soft tissue den-
sity mass in the pelvis (Figure 4). She underwent a combined
procedure with gynecologic oncology and vascular, general,
and cardiothoracic surgery, all present. Redo-sternotomy
and laparotomy were performed, the IVC was opened after
gaining control of the proximal and distal vessels, and awhite,
firm, rubbery tumor nearly 30 cm long was excised with
gentle traction (Figure 5(a)).The internal iliac vein had tumor
remnant in it that was not resectable and the vein was ligated.
The pelvic mass was identified abutting but not invading the
sigmoid colon and was excised (Figure 5(b)). Histopathology
identified identical material to the original specimen with
strong estrogen and progesterone receptor positivity on
immunostaining (Figure 5(c)). Her postoperative recovery
was complicated by deep venous thrombosis of her right
lower limb, treatedwithwarfarin.Her recoverywas otherwise
unremarkable and she was commenced on Anastrozole 1mg
daily as per oncologic recommendation. She continues to
remain well six months following her hospital discharge with
ongoing oncology follow-up.
4. Discussion
Uterine leiomyoma is themost common benign pelvic tumor
in women [1, 2]. Direct intravascular growth can occur in




Figure 4: (a) CT axial and (b) coronal views of the IVL in the right common iliac vein (red arrows). (c) Axial and (d) coronal views of the
pelvic component of the tumor (red arrows), abutting the dilated common iliac vein (yellow arrow). (e) Axial T2-weighted sequence onMRI
identifying the intraluminal caval tumor with (f) associated pelvic mass on coronal image.
up to 30% of cases, with intravenous leiomyomatosis (IVL)
defined as intravascular proliferation of benign-appearing
smooth muscle tumor in the absence of, or beyond the
confines of, a leiomyoma [3]. Almost all involved vessels are
veins, or rarely lymphatics, and intra-arterial growth has not
been described [3]. Any patient with intravenous invasion
of leiomyoma identified either at initial surgical resection
or on histological examination should be followed up with
surveillance imaging, as these patients have the potential for
propagation of the remnant tumor into the venous system.
Cardiac extension (CE) is an uncommon sequelae of IVL,
occurring in less than 10% of cases [4]. The smooth muscle
cells proliferate and extend cranially up the inferior vena cava
to the right heart, with potential to project into the right
ventricle and pulmonary vasculature as a serpentine-like
mass [5]. Intracaval growth is often asymptomatic until the
right heart is reached [5–7]. Echocardiography is frequently
first to identify the right-sided cardiac mass [5–7] and
these lesions can be mistaken for primary cardiac tumors,
most commonly myxoma [1–3, 5, 8]. Tumor embolism is
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Figure 5: (a) Gross specimen of the tumor resected from the IVC venotomy during second-stage procedure and (b) pelvic mass with venous
attachment site (yellow arrow) with (c) strongly positive staining of IVC tumor specimen for estrogen receptors.
very uncommon. This may be due to the dense fibromus-
cular and vascular composition of IVL which also lacks
necrosis and hemorrhage [1, 2, 6]. Cardiac extension (CE)
of IVL carries significant risk of morbidity and mortality,
primarily from venous obstruction and cardiac insufficiency
[4, 9–11].
Intravascular extension with cardiac involvement was
first reported in 1907 [5, 12, 13]. Since that time, reports of
IVL with CE have continued to increase in the literature
[5–7, 14]. The majority of the current literature focuses on
the presentation, risk factors, radiologic findings, surgical
treatment, and outcomes [5–7, 15]. These reports clearly
demonstrate that complete surgical resection should be the
initial goal of therapy, as it offers almost certain cure [6,
7, 15]. However due to the indolent clinical course and
often late presentation, as demonstrated by both our cases,
many patients have extensive intravascular tumor that is
not amenable to complete resection. The lung lesions that
developed following resection of the intravascular tumor of
our first case were diffuse and not accessible for resection or
biopsy. Our second case had intravenous extension of IVL
deep into the pelvis via the internal iliac vein, which was not
amenable to safe resection, requiring ligation of the affected
vein. Furthermore, some patients may choose not to undergo
operative intervention. In light of these issues, the uses of
medical treatments, which aim to reduce tumor volume or
at least slow the progression of the tumor growth, have been
trialed. The role of hormonal therapies for patients who
cannot or are unwilling to have complete operative resection
and the key principles for operative treatment of IVL with CE
are discussed in this study.
4.1. Treatment: Surgery. The first successful operative resec-
tion of IVL with CE was reported in 1980 [16]. Since then
multiple reports and reviews have discussed ideal operative
technique for resection of IVL with CE [17–19]. Three con-
clusions can be drawn from the current literature in regard
to surgical treatment. Firstly, complete surgical resection
should be the goal of therapy as this offers almost certain
cure and should occur promptly following discovery and
diagnosis [6, 7]. Incomplete resection has a recurrence rate
of up to 33% [6], with some authors reporting rapid regrowth
following resection of the cardiac portion [20, 21].The tumor
can also recur following subtotal resection despite peripheral
estrogen deprivation via medical therapy or total hysterec-
tomy and bilateral salpingo-oophorectomy, further empha-
sizing the importance of complete excision where possible
[15].
Secondly, the intracardiac portion of the tumor should
be urgently resected if the patient presents with any signs
of cardiac obstruction or failure [6, 7]. However, com-
plete tumor excision from the chest alone should not be
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attempted, as reports of this approach have resulted in
death from tearing the IVC and retroperitoneal hemorrhage
[13, 22].
Finally, either a single- or multistage operative approach
can be used with similar low intra- and postoperative com-
plications. The urgency, surgical approach, and combination
or separation of abdominal and thoracic procedures depend
on the presentation, extent of the tumor, patient factors, and
surgical services available [7, 23]. A staged procedure involves
resecting the cardiac component of the tumor first, followed
by an abdominal approach for the remaining IVC and pelvic
tumor components [17, 24]. The second approach utilizes a
single-stage abdominothoracic operation with a combined
sternolaparotomy and cardiopulmonary bypass with or with-
out deep hypothermic circulatory arrest [23]. Both have been
performed with minimal operative morbidity and mortality,
and either approach can be used depending on the extent of
the pelvic and intravascular extent of the tumor [7]. More
recently, a third approach has been described using a single-
staged procedure utilizing an abdominal-only incision.These
authors reported complete resection of the entire tumor via
an abdominal IVC venotomy, without the use of cardiopul-
monary bypass, or circulatory arrest [17]. While there are
concerns about tumor embolization, the authors state that
this risk is extremely low. Confident diagnosis preoperatively
is required as other caval-infiltrating tumors such as renal-cell
carcinoma have a much higher propensity for tumor fracture
or embolization [17]. Regardless of approach, intraoperative
transesophageal echocardiography should be performed to
visualize the proximal end of the tumor and help guide
complete resection [6, 7, 17].
4.2. Treatment: Medical Therapy. The use of hormonal ther-
apy in IVL with CE was initially trialed on the theoretical
basis that the tumor has similar hormonal characteristics to
myometrial tissue and uterine leiomyoma [7]. If effective,
hormonal treatment could slow disease progression and
allow patients to continue with minimal symptoms following
incomplete resection. It may also provide a treatment option
for patients who refuse, or are unfit for, surgery. The other
favorable characteristic for hormonal therapy in IVL with CE
is that patients have almost uniformly undergone previous
hysterectomy, so the consideration of fertility preservation
in association with hormonal management is usually not
required.
Hormonal therapies used in IVL with CE aim to induce
a state of systemic hypoestrogenism, thereby starving tumor
cells of their hormonal growth stimulus. Early reports of post-
operative hormone therapy after complete surgical resection
recommended against their use as side effects are common
due to the systemic nature of hormonal treatment as well
as the realization that complete surgical excision offered
curative treatment. This meant that these treatments were
no longer needed following surgery in most reported cases.
Recent reviews of IVL with CE treatment state that the use
of hormone treatments such as Tamoxifen, Letrozole, or
Methoxyprogesterone does not offer survival benefits or pre-
vent tumor recurrence following incomplete excision [6, 7].
Not all classes of available hormonal agents were scrutinized
in this review though, and it is unclear about the follow-
up of treated patients and whether they were adherent to
treatment regimes. Our two cases demonstrate the potential
for IVL to recur at the operative site as well as presenting as
new disease in a remote site, most commonly the lungs. Both
cases highlight the need for further treatment if the tumor
cannot be confidently excised in entirety, regardless of the
location of the residual tumor. It is clear from our first case
that hormonal treatment can have varying effects on IVLwith
CE, depending on the class of agent used. Using aromatase
inhibition provided our patient with disease-free progression
and symptom-free daily life for over ten years, including
having no reportable side effects of AI use at last known
follow-up. Our second case highlights the benefits of single
agent therapywith a relatively favorable side effect profile that
can be safely used in patients following incomplete resection.
This review discusses the use of all hormonal treatment
described in the literature and their results in the treatment
of IVL with CE.
4.2.1. Progesterone. The first hormonal therapies for uterine
leiomyoma were reported in the early 1980s. Leiomyoma
expresses both estrogen and progesterone receptors, with
estradiol able to induce progesterone receptor expression and
support progesterone action on leiomyoma tissue [25]. In
uterine leiomyoma, two studies using depot-medroxypro-
gesterone acetate (DMPA) demonstrated disease regression
and improvement of symptoms [11, 26]. Evans and Cramer
though reported increased lesion size and worsening of
symptoms [9, 10]. Despite IVL displaying similar proges-
terone receptor characteristics to uterine lesions, there is little
evidence surrounding the use of progesterone deprivation for
the treatment of IVL. The development of targeted estrogen
therapy has superseded the use of progesterone therapy, and
there are no recent reports of progesterone use in treatment
of IVL with CE.
4.2.2. Selective Estrogen Receptor Modulators (SERMs).
SERMs are nonsteroidal estrogen receptor ligands that dis-
play tissue specific agonist-antagonist estrogenic action [25].
Leiomyomas express estrogen receptors and demonstrate
increased growth during hyperestrogenic states [7]. Although
initial results were favorable, the use of SERMs for treatment
of uterine leiomyomas has not shown consistent evidence
that this treatment reduces tumor size or improves clinical
outcomes [27, 28]. However SERMs such as Tamoxifen
and Raloxifene have been used as both monotherapy and
adjuvant treatment for IVL with CE.
An analysis of 194 cases of IVL with CE concluded that
postoperative antiestrogen therapy using Tamoxifen did not
prevent tumor recurrence [6]. Studies were limited to case
reports and series only. This recommendation is in keeping
with the outcome of our first case, which developed pul-
monary lesions following resection of the caval portion of her
IVLwithCE. Similarly, Lewis and colleagues reviewed the use
of Tamoxifen in BML, which is histologically similar to IVL,
with benign leiomyoma cells depositing in the lungs. This
group found that Tamoxifen prevented disease progression
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in only 2 of 10 cases; the remaining 8 cases had disease
progression [29].
In addition to these treatment results, SERMs such as
Tamoxifen are also not recommended for use in women with
a previous history of thrombotic events such as deep venous
thrombosis (DVT), stroke, and pulmonary embolus (PE).
Considering that many patients with IVL with CE present
with symptoms suggesting PE or DVT, this treatment is
not appropriate for these patients. The use of Tamoxifen in
our first case essentially demonstrates a similar response to
many other documented cases of its use in IVL with CE. It
may have restricted the progression of the tumor initially;
however this may also simply be attributable to the slow
progressive nature of the tumor. After one year of treatment
with Tamoxifen, new pulmonary lesions had developed and
treatment was switched to an aromatase inhibitor. Tamoxifen
also has a range of adverse effects, which contribute to the
unsuitability of long-term antiestrogen therapy and were
experienced by our first patient. Primarily, agonistic effects
on the estrogen receptors of the endometrium increase the
risk of endometrial carcinoma [25], as well as menopause
induction, osteoporosis, and cardiovascular disease [28].
4.2.3. Gonadotropin-Releasing Hormone (GnRH) Agonists.
The use of GnRH agonists has been increasingly investigated
for the treatment of uterine leiomyoma, as well as breast
and prostate cancer. GnRH agonists are a synthetic peptide
modeled after the hypothalamic neurohormoneGnRHwhich
interacts with the receptor to release pituitary hormones
FSH and LH, causing systemic estrogen and progesterone
suppression [30]. Through the direct, competitive inhibition
of the pituitary GnRH receptor, GnRH agonists have been
used to prevent recurrence of IVL with CE by inducing a
state of hypoestrogenism [31, 32]. Hameleers and colleagues
described treating a patient for a period of three years with
a GnRH analogue following incomplete resection of IVL
with CE. She had a small growth in her residual tumor
but remained clinically asymptomatic [33]. Mitsuhashi and
colleagues reported the use of the GnRH agonist leuprorelin
acetate for six months following the incomplete resection of
the pelvic component of IVL with CE, which was confirmed
to be estrogen receptor positive. The tumor began to grow
following the cessation of GnRH agonist therapy, and growth
was inhibited once the therapy was recommenced [31]. Both
Jung Choi and Morice describe the use of GnRH agonist
following a single-stage resection of IVL with CE, both with
a pelvic mass also requiring resection. No progression of
disease was seen following six and ten months of treatment,
respectively [4, 34].
The main concerning features of long-term therapy with
GnRH agonists are a reduction in bone mineral density
caused by low circulating estrogen levels [35, 36]. Other
side effects associated with these hormonal changes include
vasomotor symptoms such as hot flushes and headaches and
an altered lipid profile predisposing to cardiovascular disease
[36]. Long-term use has resulted in attempts to offset these
effects through a technique of “adding back” steroid support
through the use of other agents, including SERMs such as
Raloxifene [36]. There are no reports of this application of
therapy to IVL with CE.
4.2.4. Aromatase Inhibitors (AIs). Aromatase catalyzes the
final step in estrogen synthesis, converting the androgens
androstenedione and testosterone to the estrogens estrone
and estradiol [37]. AIs are a class of antiestrogens that
potently inhibit the aromatase enzyme in all tissues. AIs
reversibly bind to the aromatase enzyme complex and sup-
press over 95% of tissue aromatase activity.This results in sig-
nificant reductions in systemic circulating estrogen and has
no effect on the formation of adrenal corticosteroids or aldos-
terone [37, 38]. First-generation AIs were used in estrogen-
receptor positive postmenopausal breast cancer. Now, third-
generation nonsteroidal inhibitors such as Anastrozole and
Letrozole are most commonly used in clinical practice,
remaining primarily in estrogen and progesterone-receptor
positive breast cancer [39]. Leiomyoma also expresses strong
ER positivity and AIs have been the focus of several studies
looking at their effects on size, symptom improvement, and
other outcomes such as arterial blood supply in uterine
leiomyoma [40–45]. While the current levels of evidence
are insufficient to provide strong clinical recommendations
for the use of AIs in uterine fibroids [46], several articles
have reported the potential advantages over other hormonal
treatments [40–43]. Parsanezhad et al. directly compared the
3rd-generation AI Letrozole to the GnRH agonist Triptorelin
in a randomized controlled trial investigating their effects on
leiomyoma volume and hormonal status [42]. They demon-
strated a trend towards greater uterine leiomyoma volume
reduction with AI treatment compared to a GnRH agonist,
with a much more favorable side effect profile. They also
commented that AI use did not alter systemic hormonal
profile. Gurates and Hilário both demonstrated that AIs
had a minimal side effect profile and reduced the size
and symptoms of uterine leiomyoma [40, 41]. Brito et al.
demonstrated in a small study that there was no change in
uterine blood flow with the use of AIs in uterine leiomyoma,
suggesting that the effects of the therapy are strictly based
on the hormonal blockade and not vascular in nature [43].
AIs are particularly useful in leiomyoma treatment based on
this finding, as leiomyoma cells produce their own estrogen,
with AIs inhibiting the estrogen production from these cells
as well as normal ovarian and adipose cells [47–49]. Lewis
et al. discuss a case of IVL with CE and pulmonary lesions
who underwent resection of the cardiac portion of her
tumor only, followed by treatment with an AI (Anastrozole)
with initial symptomatic improvement. The patient ceased
her AI treatment and represented with symptom recurrence
from her IVC mass. While the pathology is similar but not
identical, BML has 5 case reports in the literature of AI use.
All patients had stable or improved disease on follow-up
[29, 50].
Only a single case report for AI use in IVL with CE is
available in the current literature. This report by Biri and
colleagues describe the use of Letrozole in a 39-year-old
woman who had pelvic recurrence of incompletely resected
IVL [51]. After 6months of treatment, repeat imaging showed
no progression of her pelvic disease.
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Our two cases represent the only other reports of AI use
in IVL with CE and the first reports of the use of Anastrozole
specifically. In our two cases, the tumors of both patients had
strong estrogen receptor positivity confirmed on histological
staining. While long term follow-up is not yet available for
our second case, Anastrozole use has proven to be an effective
therapy in our first case, with no tumor growth of either
lung nodules or intravenous tumor recurrence over a ten-year
period.
Bonemineral density loss and vasomotor symptoms such
as flushes are themost commonly reported side effects of AIs.
However, these are reported less frequently than with GnRH
use [42]. The mechanism for this is not completely under-
stood; however it is most likely due to the maintenance of
near-physiologic systemic hormone profile. Our second case
underwent bone mineral densitometry prior to commencing
her anastrozole therapy and prophylactically commenced on
oral vitamin-D supplementation.
5. Conclusion
Surgical excision of IVL with CE offers curative treatment
and can be performed using either a single- or multistaged
operative approach. If complete resection is not achieved
ongoing treatment with hormonal agents should be consid-
ered as the recurrence rate can be over 30%. The use of
hormonal therapies traditionally used in uterine leiomyoma
for suppression of the estrogen-sensitive growth of IVL with
CE has yielded mixed results. Aromatase inhibitors are a
relatively recent treatment addition to the hormonal blockade
of estrogen-dependent tumors. These agents can potentially
provide patients with incompletely resected IVL with CE,
with progression-free survival in the short to medium
term.
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